We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

MacroGenics Inc (MGNX) USD0.01

Sell:$16.40 Buy:$16.44 Change: $0.93 (5.37%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.93 (5.37%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.93 (5.37%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

MacroGenics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company's lead product, MARGENZA, is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. In addition, the Company has a pipeline of product candidates in human clinical testing, including eight immuno-oncology programs, such as Flotetuzumab (CD123 x CD3), Retifanlimab (PD-1), Enoblituzumab (anti-B7-H3), Tebotelimab (PD-1 x LAG-3), MGD019 (PD-1 x CTLA-4), MGC018 (B7-H3), IMGC936 (ADAM9) and MGD014 (HIV x CD3). These pipelines are created primarily using its antibody-based technology platforms.

Contact details

9704 Medical Center Dr
United States
+1 (301) 2515172

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.02 billion
Shares in issue:
61.26 million
United States
US dollar

Key personnel

  • Scott Koenig
    President, Chief Executive Officer, Director
  • James Karrels
    Chief Financial Officer, Senior Vice President, Corporate Secretary
  • Ezio Bonvini
    Senior Vice President - Research, Chief Scientific Officer
  • Stephen Eck
    Senior Vice President, Clinical Development and Chief Medical Officer
  • Eric Risser
    Senior Vice President - Business Development and Portfolio Management and Chief Business Officer
  • Thomas Spitznagel
    Senior Vice President - Bio Pharmaceutical Development and Manufacturing
  • Jeffrey Peters
    Vice President, General Counsel
  • Lynn Cilinski
    Vice President, Controller, Treasurer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.